Revelation Biosciences Inc., a Menlo Park, Calif.-based clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, closed a non-brokered private placement financing, raising gross proceeds of $9.1m.

The financing was led by Global Health Investment Advisors.

The company, which sold 628,930 shares of Series A Preferred Stock and 808,877 shares of Common Stock at a purchase price of $6.36 per share, intends to use the net proceeds for general working capital purposes and the development of REVTx-99 and REVDx-501.

The funding will also facilitate investigation into additional indications for REVTx-99, along with general and administrative operations.

Revelation Biosciences is a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company has several product candidates in development:

• REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS-CoV-2 infection. An expansion of REVTx-99 therapeutic indications is planned, targeting early treatment and prevention of respiratory viral infection such as influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity.
• REVTx-200 is based on the same technology used in REVTx-99.
• REVDx-501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection regardless of virus type without the need for specialized instrumentation.